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Objectives: Compliance to osteoporosis drugs is frequently very low, leading to 
an increased fracture risk. We investigated the factors associated with fracture 
risk in women with postmenopausal osteoporosis (PMO) in Hungary, with a focus 
on compliance. MethOds: This retrospective analysis of data from the National 
Health Insurance Fund Administration included women aged ≥ 50 years with a 
diagnosis of osteoporosis (ICD-10 codes, M80 or 81), who started an osteoporosis 
drug prescription between Jan 2004–Dec 2012 (index event) and had a 13-month 
non-treatment period prior to this prescription. The relationship between all 
factors (covariates) and fracture risk was assessed using a dynamic Cox regres-
sion model and Andersen-Gill analysis, estimating 95% confidence intervals. 
Compliance was measured using the medication possession ratio (MPR); MPR≥ 80% 
at 1 year was considered compliant. Results: A total of 181,239 patients matched 
the inclusion criteria; 40.4% of patients were > 70 years old and 12.2% had prior 
fractures in the 36-month period before each index date. Compliant patients had a 
35% (RR= 0.65, CI= 0.59-0.72) fracture risk reduction versus non-compliant patients. 
Patients aged 70-79 years, and > 80 years, had an increased fracture risk of 71% 
(RR= 1.71, CI= 1.54-1.90) and 118% (RR= 2.18, CI= 1.94-2.46), respectively, compared 
to patients aged 50-60 years. Prior fractures were associated with a 32% increased 
risk of one new fracture (RR= 1.32, CI= 1.18-1.49), and with a 90% increased fracture 
risk (RR= 1.90, CI= 1.64-2.19) in patients with 2+ prior fractures, respectively, com-
pared to patients with no prior fractures. There was also a relationship between 
any co-medication and fracture risk, with a 12% (RR= 1.12, CI= 1.03-1.22) increase 
with one co-medication and an 11% (RR= 1.11, CI= 1.01-1.21) increase with 2+ co-
medications compared to none. cOnclusiOns: Compliance was associated with 
protection against fracture (reduction of relative fracture risk). However, age, any 
co-medication and prior fractures were associated with an increased relative risk 
of fracture.
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Objectives: Persistence to orally and/or frequently administered osteoporosis 
treatments is poor. Indeed, previous retrospective research has shown that approx-
imately 50% of patients discontinue oral treatments within one year. Denosumab 
is administrated as a treatment for postmenopausal osteoporosis (PMO) via a sub-
cutaneous injection once every 6 months, and better persistence with denosumab 
has been shown in randomized trials. The current study estimated treatment 
persistence among women initiating denosumab for PMO in Sweden. MethOds: 
The study included post-menopausal women who initiated denosumab between 
May 2010 and July 2012 in the Swedish National Prescription Register. One injection 
of denosumab was defined as 6 months of persistence. Patients were considered 
persistent for an additional 6 months if they filled their next denosumab prescrip-
tion within 6 months + 56 days (permissible gap). Subgroup analyses included 
comparisons of pre-treated vs. treatment-naïve patients to other osteoporosis 
treatments, and of patients initiating denosumab treatment in 2010/2011 vs. 
2012. Results: The study identified 2,315 incident users of denosumab. Mean (SD) 
age was 73.7 (9.0) years and 60.7% were pre-treated. 83% (CI95:81-84) of patients 
were persistent at 12 months, 69% (CI95:67-71) at 18 months and 62% (CI95:60-65) at 
24 months. Increasing the permissible gap to 90 or 180 days resulted in 12-month-
persistence of 85% and 91%, respectively. Pre-treated patients were more persistent 
than treatment-naïve patients after 18 (71% vs. 67%) and 24 months (65% vs. 58%), 
but not at 12 months. No difference was observed between patients starting their 
treatment during 2010/2011 and 2012. cOnclusiOns: Among Swedish women 
with PMO, persistence to denosumab treatment is high, and pre-treated patients 
are more persistent than treatment-naïve patients. Given the poor persistence to 
oral osteoporosis treatments, denosumab treatment could, in these patients, be 
considered a relevant alternative to increases persistence and hence optimizes 
outcomes in PMO.
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Objectives: Persistence and compliance with prescribed medication are 
important factors in treatment success. This study calculated persistence and 
compliance to treatment among postmenopausal women with osteoporosis in 
Hungary. MethOds: This retrospective analysis of data from the National Health 
Insurance Fund Administration included women aged ≥ 50 years with a diagnosis 
of osteoporosis (ICD-10 codes, M80 or 81), who started an osteoporosis prescription 
(including bisphosphonates, strontium ranelate, hormone replacement therapy, 
parathormone and denosumab) between January 2004 to December 2012. We esti-
mated 12- and 24-month persistence per active substance and administration type, 
with an 8-week grace period; and measured compliance using the medication pos-
session ratio (MPR; MPR≥ 80% at 12-months considered compliant). Results: A 
total of 288,194 patients matched the inclusion criteria;43.8% were aged > 70 years 
and 6.6% had prior fractures at first index date; 84.4% and 3.1% were receiving 
oral and intravenous bisphosphonates, respectively, and 12.5% other osteoporosis 
therapies. 12-month persistence to oral and injectable drugs was 31% and 76%, 
respectively. 12-month persistence was lowest for daily (23%) and monthly (27%) 
versus quarterly (58%) and half-yearly (84%) administration (100% persistence and 
compliance assumed for yearly administration), declining at 24 months to 10%, 
10%, 36% and 44% for daily, monthly, quarterly and yearly drugs, respectively (24-
month persistence to half-yearly drugs not available). Only 46% of patients were 
compliant with treatment, with compliance higher for injectable (daily, quarterly, 
Prospective data on distance covered due to RA (paid and non-paid, self and car-
egiver’s transport) and about number of medical home visits were gathered during 
6 months observation after discharge of non-selected RA patients from one tertiary 
academic hospital. Patients were stratified according to their DAS28-CRP and HAQ-DI. 
Spearman rang correlation coefficient test was used for statistical analysis. Results: 
A total of 205 consecutive RA patients included into the study were stratified in 5 
groups: A: DAS-28CRP ≤ 5.1 (89 patients), B: DAS28-CRP > 5.1 (116 patients), I: HAQ-DI 
≤ 1 (51 patients), II: HAQ-DI ≤ 2 and > 1 (88 patients) and III: HAQ-DI > 2 (66 patients). 
In the whole study group 157 (77%) patients used transport for a mean distance of 
461 kilometers in 6 months. Corresponding values for group A, B, I, II and III were 
as follows: 67% for 329 km, 84% for 563 km in B, 55% for 159 km in I, 81% for 528 km 
in II and 88% for 605 km in III. 7 patients used home visits (3% for a mean number 
of 0.1 visits - 2% for 0.2, 4% for 0.2, 0% for 0, 1% for 0.3 and 9% for 0.3 in A, B, I, II and 
III, respectively). There was significant positive correlation between disability and 
both proportion of patients using transport and distance covered (both p< 0.0001), 
between disability and home visits and between disease activity and transport (both 
p< 0.01). cOnclusiOns: Problems with moving around and need for travelling due to 
the disease result in significant resource use in RA patients. Comprehensive services 
meeting these needs may diminish the burden of disease in Poland.
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Objectives: To assess informal care use in relation to disease activity (DAS-28CRP) 
and disability index of the Health Assessment Questionnaire (HAQ-DI) in Polish 
patients with rheumatoid arthritis (RA). MethOds: Data on amount of time con-
sumed for informal care (unpaid assistance of family member or other caregiver) 
was collected during a prospective one center cohort observational study of non-
selected RA patients discharged from tertiary academic hospital. At enrollment 
patients were divided according to DAS28-CRP and HAQ-DI. Observational period 
was 6 months. Spearman rang correlation coefficient test was used to investigate 
the relationship between informal care and disability. Results: A total of 205 
patients were included in the analysis: 89 with DAS-28CRP ≤ 5.1 (group A), 116 with 
DAS28-CRP > 5.1 (group B), 51 with HAQ-DI ≤ 1 (group I), 88 - with HAQ-DI ≤ 2 and > 1 
(group II) and 66 patients with HAQ-DI > 2 (group III). 164 (80%) patients have been 
looked after by informal caregivers (64% and 92% in A and B, respectively, and 47%, 
89% and 94% in I, II and III, respectively). Mean number of hours of informal care per 
patient during 6 months was 467 (336, 567, 153, 412 and 783 hours in A, B, I, II and 
III, respectively). There were significant (p< 0.0001) positive correlations between 
both disease activity and disability index and both number of patients being looked 
after by informal caregivers and number of hours of informal care. cOnclusiOns: 
Informal care involves substantial time inputs depending on disease activity and 
functional status of the care receiving RA patients. On one side, improving access to 
formal caregiving might be a good solution to improve quality of life and enhance 
productivity of present informal caregivers in Poland. On the other side slowing 
down the disease process might reduce the need of informal care for RA patients.
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Objectives: Postmenopausal osteoporosis (PMO) leads to an increased risk of 
fractures, which in turn is associated with high resource utilisation. DEXA scans 
measure the patient’s bone mineral density and are an important tool in assess-
ing fracture risk. We aim to determine if the monitoring of PMO patients using 
DEXA scans is associated with lower incidence of fracture. MethOds: Analysis 
was undertaken using data from the 2012 Adelphi Osteoporosis Disease Specific 
Programme (DSP), a cross-sectional survey of patients with osteoporosis across the 
EU5 and the US. Physicians completed a detailed patient record form (PRF) for the 
next 10 consulting osteoporosis patients. The PRF captured patient information 
which included age, BMI and physician-perceived severity of the patient’s osteo-
porosis as well information on fracture history, DEXA scans received and date of 
diagnosis. Bootstrapped survival time regression using an exponential distribu-
tion on time to fracture was used to determine the hazard ratio (relative fracture 
risk) for those that had received a DEXA scan, compared with those that had not. 
Other covariates in the model were age, BMI, severity, and the possibility that the 
likelihood of a DEXA scan increases with duration of time since diagnosis. Results: 
Of the 2508 PMO patients with complete information required for the analysis, 1107 
had received a DEXA scan (and had associated treatment intervention) and 1401 
had received no DEXA scan. Patients who had received a DEXA scan had 59% (0.594, 
p= 0.006) of the fracture risk of those who had received no DEXA scan, adjusted by 
possible confounders (ceteris paribus). cOnclusiOns: Patients tested with DEXA 
scans were associated with a significantly lower risk of fracture than those patients 
who were not. Over time increased use of DEXA testing could lead to a reduction in 
fractures and subsequently lower resource use and disease burden.
MuScular-SkeleTal diSorderS – Patient-reported outcomes & Patient 
Preference Studies
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mated, where EQ-5D was regressed on 1) eight SF-36 scores; 2) as per 1) plus squared 
and pair-wise interaction terms, 3) as per 1) plus clinical characteristics; and 4) as 
per 3) plus squared and pair-wise interaction terms, respectively. Model 2 and 4 were 
developed by using stepwise regression analyses. Model goodness of fit was examined 
by using Akaike information criterion (AIC), R2, and adjusted R2. Predictive perfor-
mance was evaluated by using root mean square error (RMSE). Results: Model 1 with 
eight SF-36 scores explained more than 59% of the variation in EQ-5D utility values. 
The best-performing model based on goodness of fit and predictive performance was 
model 4 (AIC= ◽-200.4, R2= 0.767, adjusted R2= 0.709, RMSE= 0.090). The model included 
four SF-36 scores (GH, MH, PF, and RP), five squared terms, twelve pair-wise interaction 
terms, and log transformed simplified disease activity index (SDAI). Also model 2, 
which included no clinical characteristics, had similar predictive ability (AIC= ◽-195.0, 
R2= 0.764, adjusted R2= 0.699, RMSE= 0.093). cOnclusiOns: EQ-5D utility values can be 
predicted from SF-36 scores and SDAI with Japanese patients with RA. The mapping 
model can be applied to SF-36 datasets to produce utility scores for economic evalua-
tion of RA treatments from the perspective of Japan health care system.
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Objectives: Rheumatoid arthritis is (RA) associated with numerous comorbidities 
that have major impacts on patients’ quality of life. The purpose of this study is 
of twofold, first, to measure the health related utilities on patients with RA using 
time trade-off (TTO) and EQ-5D and to examine how these different measures were 
related to a disease specific measure, Health Assessment Questionnaire (HAQ) and 
disability level of RA. Second, to investigate absenteeism and presenteeism using 
Work Productivity and Activity Impairment Questionnaire for Patients with RA 
(WPAI-RA). MethOds: Face-to-face patient interviews on patients with mild RA 
(DAS < 3.2), moderate RA (3.2< = DAS< 5.1) and severe RA (DAS> = 5.1) have been car-
ried out since June 2013 at rheumatology outpatient clinics at four hospitals located 
in northern, central and southern Taiwan, and will be continued until the desired 
sample size of 120 is attained. Health state utilities were elicited using time trade-
off (TTO), visual analogue scale (VAS) and EQ-5D. Productivity losses and activity 
limitation were measured by WPAI-RA. The mean value of the total HAQ score is 
the mean of the scores for the eight categories: dressing, rising, eating, walking, 
hygiene, reach, grip and usual activities. Results: Based upon the preliminary 
sample collected, the mean age was 54.5 years, mean history of disease was 8.16 
years, and 77% were female in the study patients. The mean health utility was 0.87 
(EQ-5D), 0.72 (VAS) and 0.75 (TTO). The mean value of the total HAQ score is 0.83. 
Employed patients reported 10% reduced work productivity in the previous week, as 
well as 21.0% reduced productivity in daily activities (all patients). cOnclusiOns: 
EQ-5D and VAS are consistent measures for HAQ and have high potentials for use 
in assessing the well-being of the patients with RA in Taiwan. Productivity losses 
associated with absenteeism and presenteeism are substantial.
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Objectives: For patients with rheumatoid arthritis (RA), convenience, frequency 
of dosing, and invasiveness vary greatly across different administration routes and 
may influence their everyday lives. The objective of this study was to investigate 
the impact of administration method on patients’ quality of life, understand their 
resulting unmet needs, and establish an overall preference for method of admin-
istration for RA treatment. MethOds: Patients from France, UK, Germany, Italy, 
Spain, Belgium, Sweden, and The Netherlands diagnosed with RA by a physician and 
taking prescription medication – disease-modifying anti-rheumatic drug (DMARD) 
monotherapy, biologic monotherapy, or DMARD and biologic combination therapy 
– completed a 20-minute online survey. Patients were asked about: 1) benefits and 
drawbacks of their current treatment administration method; 2) their preference 
for twice-daily oral therapy versus injection or intravenous (IV) infusion therapy if it 
met their safety and efficacy expectations; 3) if told by their doctor that they needed 
to change their current RA therapy, would they switch to twice-daily oral tablets, 
injections, or IV infusion if efficacy and safety requirements were met. Results: 
1400 patients were included: n= 250 patients in each of France, UK, Germany, Italy, 
and Spain and n= 50 in each of Sweden, Belgium, and The Netherlands. Oral DMARDs 
were seen as having more benefits and fewer drawbacks than DMARD injections, 
biologic injections, and IV therapy. The majority of patients (79%) would prefer a 
twice-daily oral tablet than an injection or IV infusion (21%) if it met efficacy and 
safety expectations. If told by their doctor that they needed to change their current 
RA therapy, 83% of all patients would prefer switching to twice-daily oral tablets over 
injection (13%) or IV infusion (4%). cOnclusiOns: Oral therapy can meet some of 
the key practical and emotional unmet needs RA patients face with injectable or IV 
infusion therapy, providing efficacy and safety requirements are met.
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half-yearly or yearly) (78%) versus oral (daily, weekly, or monthly) drugs (35%). The 
lowest compliance was observed with daily (24%) and monthly (34%) drugs. Less 
frequently administered drugs (except yearly) had the highest compliance with 
quarterly drugs having 63% and half-yearly drugs 70%. cOnclusiOns: This analy-
sis shows that persistence and compliance to osteoporosis treatment is very low 
in postmenopausal women in Hungary. However, higher persistence and better 
compliance was observed for injectable, less frequently administered drugs, which 
may lead to better outcomes.
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Objectives: The OS-MMAS is a disease-specific 8 item self-reported measure of 
adherence for osteoporosis patients. This study evaluated the measurement prop-
erties of its French translated version. MethOds: A cohort of women aged 55 or 
older, with post-menopausal osteoporosis (PMO) residing in France and treated with 
daily or weekly oral bisphosphonates (OBPs) were selected based on their historical 
data from the French Longitudinal Patient Database; following their visit to one of 
the participating practices. Eligible patients were given an OS-MMAS questionnaire 
for completion at home. Internal consistency was evaluated using the Cronbach’s 
coefficient and construct validity using confirmatory one factor analysis (CFA). 
Convergence validity was assessed using agreement between patients’ medication 
procession ratio (MPR) and their total score from OS-MMAS. To assess reproducibility, 
a subset of respondents received a second questionnaire approximately 3 months 
later. Reproducibility was tested using the intra-class correlation (ICC). Results: 
From a network of 1200 French general practices, 117 participated; 687 eligible 
women visited these practices during the period 20-Jul-2012 to 31-Dec-2012. Of 
these women, 218 (mean 73.2 years; SD= 8.1) completed ≥ 1 OS-MMAS. The 6 and 
12 month MPR was less than 80% for 25.7% patients and 59.1% patients, respec-
tively. Cronbach’s alpha coefficient was 0.76 and varied between 0.71 and 0.79 with 
the deletion of one item. The Chi-Square test of association between MPR (< 80%, 
> 80%) and OS-MMAS scores (< 6; 6-8; 8+) was statistically significant at 6 months 
(p= 0.025), but not at 12 months (p-value= 0.059). CFA reported a standardized root 
mean square residual of 0.06. The ICC on 70 patients was 0.24 with 95% confidence 
interval [0.01-0.45]. cOnclusiOns: This study demonstrated acceptable agreement 
between classification of patient’s adherence to OBPs assessed using French trans-
lated OS-MMAS and that using historical 6 months MPR; but also indicated that the 
construct of the OS-MMAS could be improved.
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Objectives: To obtain a comprehensive overview of the impact of TNF-inhibitors on 
the components of the burden of Rheumatoid Arthritis (RA) in Germany. MethOds: 
A systematic literature research in EMBASE, Medline, grey literature including rheu-
matology congress abstracts (ACR, EULAR, DGRh), German RA registry homepages, 
and the Information System of the Federal Health Monitoring (2002-2012) was per-
formed. Published data on the effect of TNF-inhibitors on mortality, morbidity, and 
health care resource utilization (HCRU) was included. Results: Overall, 15 partially 
overlapping full-text articles (0 mortality, 12 morbidity, 5 HCRU), 6 additional unique 
abstracts excluding encore publications (1 mortality, 4 morbidity, 1 HCRU) and two 
other sources (1 morbidity, 1 HCRU) were included in the final review. Reviewed lit-
erature reported an association of TNF-inhibitor use with a 35% lower mortality rate 
(HR= 0.65; p= 0.0004) compared to synthetic disease modifying antirheumatic drugs 
(DMARDs). Disease severity based on symptoms decreased over time in Germany: the 
chances of reaching DAS28 remission (OR= 1.97; 95%-CI: [1.20-3.21]) and functional 
remission (OR= 2.21; 95%-CI: [1.06-4.63]) were doubled, the odds of functional independ-
ence were quadrupled (OR= 4.09; 95%-CI: [1.80-9.29]) with TNF-inhibitor treatment. 
All SF-36 domains and fatigue scores increased significantly after treatment initia-
tion. TNF-inhibitor treatment is associated with fewer limitations in daily activities 
(OR= 0.77; 95%-CI: [0.65-0.90] and less perseverant limitations (OR= 0.82; 95%-CI: [0.68-
0.98]. Standardized disability pension ratios in patients with biologics use decreased 
over time from 12.5 (2001–2003) to 3.4 (2010-2011). Frequency and average duration of 
hospitalization have fallen from 2001 (19% of patients hospitalized with average dura-
tion of 19 days) to 2011 (12%, 12 days). No HRCU data was available for the outpatient 
sector or surgery. cOnclusiOns: Based on available German data, treatment with 
TNF-inhibitors is associated with lower mortality, increasing likelihood to reach clinical 
remission, better symptom control, functional status, work ability and quality of life.
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Objectives: To develop a mapping model for estimating EuroQol 5D (EQ-5D) utility 
values from Short Form 36 (SF-36) scores in Japanese patients with rheumatoid arthri-
tis (RA), with or without clinical characteristics. MethOds: Linear regression models 
were applied to a cross-sectional data set of 112 patients with RA collected from a 
regional hospital in Niigata prefecture, Japan. Four model specifications were esti-
